It is also half of the cost of anti-hypertensive drugs for the prevention of cardiovascular events and nearly 3 times less than the cost of DPP-4 inhibitors for the treatment of diabetes type 2 or the cost of antithrombotic drugs for the prevention of recurrent stroke (see appendix).15 This evidence concerns the gene DPP4 and stroke disorder.